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O R I G I N A L A R T I C L E 
Duration of Methicillin-Resistant Staphylococcus aureus Carriage, 
According to Risk Factors for Acquisition 
Jonas Marschall, MD; Kathrin Muhlemann, MD, PhD 
OBJECTIVE. To examine the duration of methicillin-resistant Staphylococcus aureus (MRSA) carriage and its determinants and the influence 
of eradication regimens. 
DESIGN. Retrospective cohort study. 
SETTING. A 1,033-bed tertiary care university hospital in Bern, Switzerland, in which the prevalence of methicillin resistance among S. 
aureus isolates is less than 5%. 
PATIENTS. A total of 116 patients with first-time MRSA detection identified at University Hospital Bern between January 1, 2000, and 
December 31, 2003, were followed up for a mean duration of 16.2 months. 
RESULTS. Sixty-eight patients (58.6%) cleared colonization, with a median time to clearance of 7.4 months. Independent determinants 
for shorter carriage duration were the absence of any modifiable risk factor (receipt of antibiotics, use of an indwelling device, or presence 
of a skin lesion) (hazard ratio [HR], 0.20 [95% confidence interval {CI}, 0.09-0.42]), absence of immunosuppressive therapy (HR, 0.49 
[95% CI, 0.23-1.02]), and hemodialysis (HR, 0.08 [95% CI, 0.01-0.66]) at the time MRSA was first MRSA detected and the administration 
of decolonization regimen in the absence of a modifiable risk factor (HR, 2.22 [95% CI, 1.36-3.64]). Failure of decolonization treatment 
was associated with the presence of risk factors at the time of treatment (P = .01). Intermittent screenings that were negative for MRSA 
were frequent (26% of patients), occurred early after first detection of MRSA (median, 31.5 days), and were associated with a lower 
probability of clearing colonization (HR, 0.34 [95% CI, 0.17-0.67]) and an increased risk of MRSA infection during follow-up. 
CONCLUSIONS. Risk factors for MRSA acquisition should be carefully assessed in all MRSA carriers and should be included in infection 
control policies, such as the timing of decolonization treatment, the definition of MRSA clearance, and the decision of when to suspend 
isolation measures. 
Infect Control Hosp Epidemiol 2006; 27:1206-1212 
Methicillin-resistant Staphylococcus aureus (MRSA) is a major meta-analysis concluded that there is no evidence that treat-
cause of nosocomial infections worldwide, resulting in sub- ment with antimicrobials can eradicate MRSA carriage.12 
stantial morbidity and mortality. Humans are the only sig- In the present study, we sought to determine the duration 
nificant reservoir of MRSA. Colonization with the microor- of MRSA carriage and how the duration is influenced by risk 
ganism is a necessary step during the pathogenesis of MRSA factors for MRSA acquisition and receipt of decolonization 
infection, and it is the source of cross-transmission between treatment. The rationale was to create a basis for the optimal 
humans.1'2 Placement of MRSA carriers in contact isolation
 t i m i n g for initiating decolonization treatment and suspending 
during their stay in healthcare institutions is a current stan- isolation measures for MRSA carriers. 
M E T H O D S 
dard of care.3'4 Although cost-effective overall, isolation mea-
sures are expensive. A recent retrospective study calculated 
an additional cost of $318 per hospitalization-day per patient 
with MRSA, of which approximately 80% was from the use study Setting and Local Infection Control Policy 
of barrier precautions around beds in multiple-bed rooms.5 
Breaks in compliance with isolation policies are a continuous University Hospital Bern (Bern, Switzerland) is a 1,033-bed 
threat for the dissemination of MRSA. tertiary care center with more than 30,000 admissions per 
Colonization may persist for months or even years.68 How- year. The referral area covers the local region, where ap-
ever, data are insufficient about the natural history of MRSA proximately 1 million inhabitants live, and a large number 
colonization and its determinants. Furthermore, the role of of smaller hospitals within and outside the Bernese region, 
topical decolonization therapy is still controversial.9"11 A large In this part of Switzerland, the prevalence of methicillin re-
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sistance among S. aureus isolates is less than 5%,13 and it 
ranges from 3% to 5% at University Hospital Bern. 
According to local written infection control guidelines, 
MRSA carriers are put into contact isolation, which involves 
stay in a single-patient room, use of gloves and gowns by 
medical personnel during physical contact, and use of masks 
by medical personnel when exposure to respiratory secretions 
is expected. In the interdisciplinary intensive care unit, con-
tact isolation is implemented in 4-bed cubicles by marking 
an isolation area of approximately 2 m around the patient's 
bed with paravents and closing the neighboring bed. Screen-
ing for MRSA involves all patients in contact with an MRSA 
carrier for whom placement in isolation was delayed and 
patients treated in a foreign healthcare institution during the 
6 months before admission. Patients with MRSA are tagged 
in the hospital's patient administration system. On readmis-
sion, tagged MRSA carriers are put into contact isolation. 
MRSA decolonization treatment comprises a 5-day course 
of nasal application of mupirocin ointment, daily skin dis-
infection with 4% chlorhexidine soap, and daily gargling with 
0.1% chlorhexidine solution. The decision for decolonization 
treatment is made by the infection control team and requires 
that systemic antibiotic therapy and indwelling devices have 
not been used for at least 14 days and that all skin lesions 
have healed. During the study period, screening for MRSA 
control was performed intermittently as convenient during 
ambulatory visits or inpatient treatment, and results were 
therefore distributed over intervals of weeks to months, in-
dependent of whether decolonization treatment had been 
administered. 
Recruitment of Study Patients and Collection of Data 
The study was performed in accordance with local ethical 
guidelines. Patients with MRSA carriage detected for the first 
time between January 1, 2000, and December 31, 2003, were 
identified retrospectively through the laboratory information 
system of the Institute for Infectious Diseases, University of 
Bern, which serves University Hospital Bern. A total of 223 
patients met these criteria. Thirty-eight patients were ex-
cluded, because they were not treated at University Hospital 
Bern at the time MRSA was first detected, and information 
concerning risk factors for MRSA acquisition was not avail-
able. An additional 69 patients were lost to follow-up after 
1 month and were therefore also excluded. A total of 116 
patients remained for analysis. 
A standardized questionnaire was used to collect patient 
data retrospectively from medical records, infection control 
unit statistics, and the laboratory information system. Follow-
up for individual patients started on the date MRSA was first 
detected and ended on December 31, 2004. 
Terms and Definition 
The following risk factors for MRSA carriage at the time 
MRSA was first detected were considered: receipt of systemic 
antibiotic therapy or performance of a surgical procedure 
during the last 30 days, presence of skin lesions (surgical site 
wounds, ulcers, and/or dermatitis), use of indwelling devices 
(intravascular central catheters, endotracheal tube or trache-
ostoma, urinary catheters, and/or wound drainage devices), 
receipt of immunosuppressive therapy (steroid treatment 
equivalent to 7.5 mg/day or more of prednisone, chemo-
therapy, or immunomodulators), presence of diabetes mel-
litus, presence of renal insufficiency, receipt of hemodialysis, 
and presence of malignant tumors. Risk factors considered 
during follow-up were the same as those for the time when 
MRSA was first detected, with the exception of performance 
of surgical interventions during the past 30 days. We calcu-
lated the sum of risk factors present at the following junctures: 
the time MRSA was first detected, the time of decolonization 
treatment (if applicable), and the time of the final MRSA 
screening during follow-up. For analysis, risk factors were 
also categorized dichotomously (3 or less vs more than 3). 
Moreover, we defined modifiable risk factors as receipt of 
antibiotic treatment within the previous 30 days, presence of 
skin lesions, and use of indwelling foreign devices. 
The total follow-up time was defined as the interval from 
the first detection of MRSA until the last MRSA screen-
ing (positive or negative). Clearance of MRSA carriage was 
assumed when 2 or more of the final screenings during 
follow-up were negative for MRSA. Long-term carriage was 
defined as persistent carriage for more than 12 months dur-
ing follow-up. 
Detection of and Screening for MRSA Colonization 
Routine MRSA screening involved testing of specimens from 
the following anatomical sites: both nares, the groin (2 spec-
imens), any skin lesions, tracheal secretions in intubated or 
tracheostomized patients, and urine in patients with urinary 
catheter. Samples obtained for suspected MRSA infection 
were included in the screening samples. Swabbing was per-
formed with twisted wire rayon-tipped applicators (Copan 
Venturi Transystem). One applicator was used for both nares 
and another for both specimens from the groin, and appli-
cators were premoistened with physiological saline. Labora-
tory screening for MRSA was performed with the mannitol-
oxacillin biplate test, selective culturing for gram-positive 
organisms, the coagulase tube test (to exclude coagulase-
negative staphylococcus), and resistance pattern testing on 
Muller-Hinton agar. Available consecutive MRSA isolates 
from the same patient were typed using pulsed-field gel elec-
trophoresis (PFGE), as described elsewhere.14 
Statistical Analysis 
All analyses were performed in StatView, version 5.0 (SAS 
Institute), or Stata, version 8 (Stata Corporation), using a 
cutoff of P value of .05 or less (2-tailed). Differences between 
means were tested by the Student's t test or the Mann-Whit-
ney U test, and proportions were compared with the x2 or 
Fisher's exact test, as appropriate. The duration of MRSA 
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colonization determinants was analyzed by Kaplan-Meier 
curves using the log-rank test and Cox regression analysis. 
RESULTS 
Characteristics of Study Patients and Risk Factors for 
MRSA Acquisition 
A total of 116 patients with newly detected MRSA coloni-
zation were followed up for a mean duration (±SD) of 
496 ± 431 days (median, 316.5 days [range, 31-1,616 days]). 
The characteristics of these 116 patients at the time MRSA 
was first detected are listed in Table 1. Almost half of the 
patients (45.7%) were 65 years or older. Male patients pre-
dominated (69.8% of the study population). Most patients 
were of Swiss nationality (80.2%) and lived in private house-
holds (90.5%). Half of the MRSA carriers (48.3%) were iden-
tified through the screening of contacts. The predominant 
anatomical sites of MRSA detection were skin lesions (39.7%) 
and the nares (35.3%). The most prevalent risk factors for 
MRSA acquisition were skin lesions (71.6% of patients), past 
antibiotic therapy (56.9%), and past surgery (54.3%). Almost 
all patients (96.6%) had been hospitalized within the previous 
6 months, and the mean hospitalization duration (±SD) 
before MRSA detection was 11.9 ± 17.7 days. Almost half of 
the patients (43.1%) had an MRSA infection at the time 
MRSA was first detected. 
Clearance of MRSA During Follow-up 
During follow-up, a mean of 3.8 MRSA screenings were per-
formed per patient per year. Sixty-eight patients (58.6%) 
cleared MRSA colonization. The median time to clearance, 
based on the Kaplan-Meier estimate, was 226 days (7.4 
months). In patients who cleared colonization, the median 
follow-up time after clearance was 189.5 days (range, 1-1,602 
days). Long-term carriage was observed in 24 patients 
(20.7%), of whom 19 cleared MRSA colonization, and 5 re-
mained colonized throughout the follow-up period. 
Independent determinants for MRSA clearance were the 
absence of modifiable risk factors (hazard ratio [HR], 0.20 
[95% confidence interval {CI}, 0.09-0.42]; P< .001), receipt 
of immunosuppressive therapy (HR, 0.49 [95% CI, 0.23-
1.02]; P = .05), and hemodialysis (HR, 0.08 [95% CI, 0.01-
0.66]; P = .01) at the time MRSA was first detected and the 
administration of decolonization treatment (HR, 2.22 [95% 
CI, 1.36-3.64]; P = .01) (Table 2). Thirty-six patients (31.0%) 
received decolonization treatment, which failed in 13 (36.1%). 
The median time to initiation of decolonization treatment 
was 37.5 days (range, 0-833 days). The median time to clear-
ance (based on the Kaplan-Meier estimate) for patients with 
0-3 risk factors at the time of MRSA detection was 43 days 
if decolonization treatment was administered and 238 days 
if it was not administered (Figure). The corresponding in-
tervals for patients with more than 3 risk factors were 221 
days if decolonization treatment was received and 597 days 
if it was not received. The 13 patients who did not respond 
to decolonization treatment had a significantly greater num-
ber of risk factors at the time of decolonization treatment 
(mean [±SD], 1.30 ± 1.37 [95% CI, 0.47-2.14]) than pa-
tients who cleared MRSA immediately after treatment (0.39 
± 0.65 risk factors [95% CI, 0.11-0.67]; P = .01). 
Intermittent Negative Results of Screenings for MRSA 
During follow-up, 30 patients (25.9%) had intermittent 
screenings with negative results, and 12 patients (10.3%) had 
2 or more consecutive intermittent screenings with negative 
results. Twelve of the 30 patients had PFGE performed on 
MRSA isolates that were obtained before and after intermit-
tent screenings with negative results; for all 12, the PFGE 
pattern for the first isolate matched the pattern for the second 
isolate. For 3 of the 12 patients, extended intervals of 33, 39, 
and 51 months occurred between the times the 2 MRSA 
isolates with an identical PFGE pattern were obtained. The 
median interval between the time MRSA was first detected 
to the time of the first intermittent screening with a negative 
result in these 30 patients was 31.5 days (range, 1-365 days), 
compared with the median time to MRSA clearance of 226 
days in the whole study population. The mean number of 
risk factors present at the time MRSA was first detected was 
higher for patients with negative results of intermittent 
screenings (mean, 3.86 vs 2.96; P = .002), and they had a 
lower probability of clearing MRSA colonization (Table 2). 
In the Cox regression analysis, the only independent factor 
associated with negative results of intermittent screenings was 
the number of risk factors present at time MRSA was first 
detected (HR, 1.65; 95% CI, 1.24-2.20; P = .005). 
MRSA Infection During Follow-up 
Of 116 patients, 17 (14.7%) developed an MRSA infection 
during follow-up. Five of the 17 patients also had an MRSA 
infection at the time MRSA was first detected. Infection oc-
curred a median interval of 123 days (range, 4-705 days; mean 
interval [±SD], 192.5 ± 212.3 days) after MRSA was first 
detected. Kaplan-Meier estimates could not be obtained, be-
cause less than 50% of patients developed MRSA infection. 
In the Cox regression analysis, only a large number of risk 
factors present at the time of the last MRSA screening (HR, 
1.41 [95% CI, 1.009-1.975]; P = .04) was significantly as-
sociated with MRSA infection. None of the other variables 
reached statistical significance, perhaps in part because of the 
small number of MRSA infections observed. 
DISCUSSION 
The time course of MRSA colonization and its determinants 
was described in a retrospective cohort of 116 patients with 
MRSA at a tertiary care university hospital. The characteristics 
of the study population corresponded to known risk factors 
for MRSA acquisition, such as older age, prior hospitalization 
(especially in the intensive care unit), previous surgery, pre-
vious antibiotic treatment, presence of skin lesions, and use 
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TABLE i. Characteristics of 116 Patients Colonized With Methicillin-
Resistant Staphylococcus aureus (MRSA) at University Hospital Bern 
(Bern, Switzerland) between January 1, 2000, and December 31, 2003 
TABLE I . (Continued) 
Characteristic Value Characteristic Value 
Age 
Mean y ± SD 
0-16 y 
17-44 y 
45-64 y 
^65 y 
Male sex 
Residence 
Private household 
Long-term care facility 
Immigrant housing facility 
Method of MRSA detection 
Clinical diagnostic workup 
MRSA screening, by patient group8 
Overall 
Contacts with an MRSA carrier 
Patients admitted from a foreign institution 
Anatomical site of MRSA detection15 
Skin lesion or wound 
Nose 
Urine 
Groin 
Respiratory tract 
Risk factor for MRSA acquisition1" 
Skin lesion(s) 
Surgery during past 30 d 
Antibiotic therapy during past 12 mo' 
During past 30 d 
During past 1-12 mo 
Indwelling device 
Immunosuppressive therapy 
Diabetes mellitus 
Renal insufficiency 
Hemodialysis 
Malignant disease 
Hospitalization history 
Stay of ^ 24 h during past 6 mo 
Length of stay, mean d ± SD 
MRSA detected during stay 
Length of stay before MRSA detection, 
mean d ± SD 
ICU history 
Admitted during current hospitalization 
Length of stay before MRSA detection, 
mean d ± SD 
MRSA infection at time of first MRSA detection 
Absent 
Subsequent infection during follow-up 
Time to subsequent onset, mean d ± SD 
55.7 ± 21.4 
6 (5.2) 
26 (22.4) 
31 (26.7) 
53 (45.7) 
81 (69.8) 
105 (90.5) 
7 (6.0) 
4 (3.4) 
60 (51.7) 
56 (48.3) 
48 (41.4) 
8 (6.9) 
46 (39.7) 
41 (35.3) 
15 (12.9) 
12 (10.3) 
8 (6.9) 
83 (71.6) 
63 (54.3) 
77 (66.4) 
66 (56.9) 
30 (25.8) 
53 (45.7) 
23 (19.8) 
23 (19.8) 
21 (18.1) 
7 (6.0) 
23 (19.8) 
112 (96.6) 
21.9 ± 22.2 
92 (79.3) 
11.9 ± 17.7 
46 (39.7) 
3.0 ± 6.3 
66 (56.9) 
12 (18.2) 
247.8 ± 227.5 
Present, by infection location 
Surgical site 
Skin or soft tissue 
Urinary tract 
Bone or prosthesis 
Respiratory tract 
Abdominal 
Sepsis 
Peridural catheter 
Surgery for MRSA infection 
MRSA infection during follow-up, 
by infection location 
Overall 
Surgical site 
Skin or soft tissue 
Urinary tract 
Bone or prosthesis 
Respiratory tract 
Sepsis 
Duration of follow-up 
Mean d ± SD 
<3 mo 
3-6 mo 
>6-24 mo 
>24-48 mo 
>48 mo 
50 (43.1) 
24 (48.0) 
8 (16.0) 
6 (12.0) 
5 (10.0) 
3 (6.0) 
2 (4.0) 
1 (2.0) 
1 (2.0) 
29 (58.0) 
17 (14.7) 
3 (17.6) 
5 (29.4) 
3 (17.6) 
1 (5.9) 
1 (5.9) 
4 (23.5) 
496.0 ± 431.4 
20 (17.2) 
20 (17.2) 
40 (34.5) 
34 (29.3) 
2 (1.7) 
(Continued) 
NOTE. Data are no. (%) of patients, unless otherwise indicated. ICU, 
intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus. 
' Includes all patients in contact with an MRSA carrier for whom placement 
in isolation was delayed and patients treated in a foreign healthcare institution 
during the 6 months before admission. 
b
 This entry totals more than 100%, because patients could have more than 
one characteristic. 
c
 Antibiotics exclude perioperative prophylaxis. 
of indwelling devices.215"21 Also, the high proportion of pa-
tients with MRSA infection at the time MRSA was first de-
tected in them (43.1%) was in accordance with earlier re-
ports.22 Because of the low prevalence of nosocomial MRSA 
carriage (3%-5% of patients) and the virtual absence of com-
munity-acquired MRSA at this institution, the likelihood of 
a new and inadvertent colonization during follow-up was 
minimal. The study has some limitations, however. The ret-
rospective study design precluded a strict schedule of follow-
up screenings and randomized the administration of decol-
onization treatment. Also, we cannot exclude the possibility 
that study patients may have received MRSA-eradication reg-
imens at another healthcare institution during follow-up. 
Fifty-nine percent of the study patients cleared MRSA 
within a median interval of 226 days (7.4 months). Two pre-
vious studies found a similar time to clearance of 7-8.5 
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TABLE 2. Determinants of Clearance of Methicillin-Resistance Staphylococcus aureus (MRSA) Coloni-
zation in 116 Patients With Newly Detected MRSA Carriage 
Variable 
Age, y 
Female sex 
No. of risk factors at first MRSA detection 
Overall 
>3 risk factors 
^ 1 modifiable risk factor 
Antibiotic therapy in past 30 d 
Skin lesion 
Indwelling device 
Surgery in past 30 d 
Immunosuppressive therapy 
Diabetes mellitus 
Renal insufficiency 
Hemodialysis 
Renal transplantation 
Tumor 
MRSA infection 
At start 
During follow-up 
Decolonization treatment 
Intermittent screenings with negative results 
Risk factor at last MRSA screening 
Overall no. 
Antibiotic therapy 
Immunosuppressive therapy 
Hemodialysis 
Clearance of MRSA 
Yes 
(n = 68) 
53.6 ± 21.1 
20 (29.4) 
2.86 ± 1.22 
25 (36.8) 
60 (88.2) 
33 (48.5) 
49 (72.0) 
27 (39.7) 
38 (55.9) 
8 (11.8) 
11 (16.2) 
10 (14.7) 
1 (13) 
5 (7.4) 
12 (17.7) 
35 (51.4) 
5 (7.4) 
29 (42.6) 
10 (14.7) 
1.06 ± 1.17 
7 (10.2) 
8 (11.8) 
1 (1.5) 
No 
(n = 48) 
58.8 ± 21.9 
16 (33.3) 
3.69 ± 1.52 
27 (56.3) 
48 (100) 
33 (68.7) 
34 (70.8) 
26 (54.2) 
25 (52.1) 
15 (31.3) 
12 (25.0) 
11 (22.9) 
6 (12.5) 
5 (10.4) 
11 (22.9) 
15 (31.3) 
12 (25.0) 
7 (14.6) 
20 (41.7) 
2.14 ± 1.54 
17 (35.4) 
14 (29.2) 
6 (12.5) 
HR (95% CI) 
1.00 (0.99-1.01) 
0.92 (0.54-1.54) 
0.77 (0.65-0.92) 
0.62 (0.38-1.01) 
0.20a (0.09-0.42) 
0.61 (0.37-0.99) 
1.13 (0.66-1.94) 
0.70 (0.42-1.18) 
1.11 (0.68-1.82) 
0.49a (0.23-1.02) 
0.75 (0.39-1.45) 
0.66 (0.33-1.30) 
0.08a (0.01-0.66) 
0.83 (0.33-2.08) 
0.86 (0.46-1.61) 
1.53 (0.95-2.46) 
0.27 (0.11-0.69) 
2.22' (1.36-3.64) 
0.34 (0.17-0.67) 
0.73 (0.59-0.90) 
0.38 (0.18-0.84) 
0.45 (0.22-0.95) 
0.19 (0.03-1.37) 
P 
NS 
NS 
.004 
.06 
<001 
.04 
NS 
NS 
NS 
.05 
NS 
NS 
.01 
NS 
NS 
.08 
.006 
.01 
.002 
.003 
.01 
.03 
.09 
NOTE. Data are no. (%) of patients or mean value ± SD. CI, confidence interval; HR, hazard ratio; NS, nonsignifi-
cant (P>.05). 
* Adjusted HR estimates are presented for the following independent determinants: modifiable risk factors, receipt of 
hemodialysis, and receipt of immunosuppressive therapy at time of first MRSA detection and decolonization treatment. 
Crude estimates are presented for all other variables. 
months.7,23 However, longer durations of 14 months8 and 40 
months6 have been reported. These differences may be ex-
plained by the frequency of infection control screening per-
formed in the different studies. For example, Vriens et al.8 
screened patients at intervals of 6 months only. A mean of 
1.6 screenings per patient per year were performed in the 
study by Sanford et al.,6 whereas we performed a mean of 
3.8 screenings per patient per year. A higher frequency of 
screenings certainly leads to a more accurate description of 
the duration of colonization. Estimates of the duration of 
colonization may also be influenced by the study population's 
size (49-197 patients were involved in the cited studies) and 
clinical characteristics. An indication for the latter might be 
the proportion of long-term carriers. In our study, approx-
imately 20% of patients were long-term carriers (defined as 
carriage of MRSA for more than 1 year), and the longest 
observed carriage time was 3.3 years. Earlier studies reported 
a lower frequency of long-term carriage of approximately 
10%.6'23'24 Lastly, different definitions used for MRSA clear-
ance may also play a role. As in our study, Sanford et al.6 
required 2 consecutive screenings with negative results; else-
where, Vriens et al8 required 1 screening with a negative result, 
and no definition was given in the study by MacKinnon and 
Allen.23 
Thirty of our 116 patients had at least 1 intermittent screen-
ing with negative results, and in 10% we observed 2 or more 
consecutive screenings with a negative result. Data on neg-
ative results of intermittent screenings are rare. Vriens et al.8 
found 6.7% of their cohort to have negative results of inter-
mittent screening, and in the study by Blok et al.25 culture-
negative intervals of 8-10 months were observed for 5 of 11 
patients with long-term carriage. Low colonization density or 
an intracellular reservoir may be responsible for negative re-
sults of intermittent screenings.26'27 Interestingly, infection 
during follow-up was more frequent among patients with 
intermittent carriage, a finding that, to our knowledge, has 
not been reported up to now. Eventually, negative results of 
intermittent screenings may lead to a premature suspension 
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FIGURE. Kaplan-Meier curves for the time to methicillin-resistant 
Staphylococcus aureus (MRSA) clearance, stratified by decolonization 
treatment and the presence of risk factors at the time of MRSA 
detection. "Log-rank test for decolonization treatment versus no de-
colonization treatment in patients with 0-3 risk factors (P = .02). 
bLog-rank test for decolonization treatment versus no decolonization 
treatment in patients with 4-7 risk factors (P = .03). 
of infection control measures. In our study, however, the 
median interval to the first intermittent screening with a neg-
ative result was considerably shorter (31.5 days) than the 
observed median time to MRSA clearance (226 days). 
Risk factors for MRSA colonization had a significant im-
pact on the duration of MRSA colonization. The strength of 
this study is the detailed analysis of a large number of risk 
factors. The presence of at least 1 modifiable risk factor (an-
tibiotic use, presence of a skin lesion, and use of an indwelling 
device), receipt of immunosuppressive therapy , and receipt 
of hemodialysis was independently associated with a longer 
duration of MRSA carriage. Earlier studies found skin lesions 
to be the most prominent factor associated with persistent 
carriage.7'8'23'25,28 Beaujean et al.28 found an association be-
tween underlying disease and persistent carriage, albeit in a 
small study population. Cystic fibrosis was identified as a risk 
factor for long-term MRSA carriage in 2 studies8'24 but was 
only present in one of our patients. All these findings suggest 
that the presence of risk factors should be considered in the 
decision to suspend isolation precautions. Beaujean et al.28 
demanded an absence of risk factors for more than 6 months 
and 3 screenings with negative results before ending isolation 
precautions. By comparison, Vriens et al.8 called for 12 
months and at least 1 screening with a negative result. On 
the basis of our findings, with an extended analysis of risk 
factors for MRSA carriage, we propose that a patient should 
be considered to have cleared MRSA colonization if at least 
2 consecutive screenings have negative results and if there are 
no other risk factors (modifiable and nonmodifiable), re-
gardless of the time that has passed since MRSA colonization 
was detected. In the presence of long-term, nonmodifiable 
risk factors, a minimum follow-up duration (eg, 6 months) 
should be allowed to elapse, to decrease the risk of false-
negative results of intermittent screenings. 
Receipt of decolonization treatment was significantly as-
sociated with the clearance of MRSA. However, it must be 
taken into consideration that, in this study, decolonization 
treatment was only administered when modifiable risk factors 
for MRSA colonization (antibiotic treatment, use of indwell-
ing devices, and presence of skin lesions) were absent. Nev-
ertheless, a high failure rate of decolonization treatment was 
observed (36.1% of patients), and failure was associated with 
the presence of nonmodifiable risk factors for MRSA colo-
nization. Vriens et al.8 reported a much higher success rate 
for decolonization treatment and concluded that such treat-
ment should be administered to all patients, independent of 
the presence of risk factors. However, the large screening 
intervals used in their study and the lack of information on 
nonmodifiable risk factors precludes a comparison with our 
findings. We suggest that decolonization treatment should 
only be given when modifiable risk factors are largely absent 
and that the success of the treatment should be evaluated 
more carefully if long-term risk factors are present. 
MRSA infection occurred in 14.7% of our patients dur-
ing follow-up. This rate is comparable with rates reported 
elsewhere.1,29 Older age, intensive care unit stay, receipt of 
hemodialysis, presence of surgical wounds, presence of pres-
sure ulcers, and use of intravascular catheters have been as-
sociated with an increased progression of MRSA colonization 
to invasive infection.1,29'30 In our study, a higher number of 
risk factors at the end of follow-up was associated with an 
increased risk of MRSA infection. 
In conclusion, modifiable and nonmodifiable risk factors 
for MRSA acquisition are the most important determinants 
of the duration of MRSA colonization and affect the success 
rate of decolonization treatments. Moreover, the presence of 
risk factors may lead to intermittent screenings with negative 
results. Risk factors should therefore be evaluated carefully 
in all MRSA carriers and should be considered in infection 
control policies, such as the timing of decolonization treat-
ment and the definition of MRSA clearance, which is the 
basis for the decision to suspend isolation measures. 
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